Formycon Shifts Strategy On US Lucentis Biosimilar

As First Patient Dosed In Ustekinumab Phase III Studies

 
• By Dean Rudge
Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.
The required pre-filing meetings with FDA are now expected to take place in early 2021 • Source: Shutterstock

More from Biosimilars

More from Products